Exosome Diagnostics Raises $20 Million for Body Fluid Based Oncology Diagnostics
Exosome Diagnostics Inc announces that it has raised $20 million co-led by NGN Capital and Forbion Capital Partners to further develop and commercialize a series of next-generation body fluid based oncology diagnostics through its proprietary, exosome based technology platform.
Read More